Trial Profile

Open-Label Rater-Blind Randomized Multi-Center Parallel-Arm Active- Comparator Study to Assess the Efficacy and Tolerability of Ofatumumab 20mg SC Monthly vs. First Line DMT - Physician's Choice in the Treatment of Newly Diagnosed RMS

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ofatumumab (Primary) ; Dimethyl fumarate; Diroximel-fumarate; Glatiramer acetate; Interferon beta-1a; Interferon beta-1a; Interferon beta-1a; Interferon beta-1b; Peginterferon beta-1a; Teriflunomide
Indications Multiple sclerosis
Focus Registrational; Therapeutic Use
Acronyms STHENOS
Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

04 Mar 2025 Planned End Date changed from 30 Jan 2026 to 13 Feb 2026.
04 Mar 2025 Planned primary completion date changed from 30 Oct 2025 to 11 Nov 2025.
15 Aug 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com